BeiGene
BGNE
#982
Rank
A$31.55 B
Marketcap
$288.42
Share price
0.49%
Change (1 day)
25.34%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

EPS for BeiGene (BGNE)

EPS in 2023 (TTM): -$25.02

According to BeiGene 's latest financial reports the company's current EPS (TTM) is -$25.98. In 2022 the company made an earnings per share (EPS) of -$30.25 a decrease over its 2021 EPS that were of -$23.75.

EPS history for BeiGene from 2015 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$25.02-17.28%
2022-$30.2527.35%
2021-$23.75-19.96%
2020-$29.6720.81%
2019-$24.5631.52%
2018-$18.68417.57%
2017-$3.61-37.16%
2016-$5.74158.95%
2015-$2.22

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$1.56-93.99%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.42-98.38%๐Ÿ‡บ๐Ÿ‡ธ USA